Form 4: Elutia CSO Michelle Williams' Stock Vesting & Tax Sale

Elutia's Chief Scientific Officer, Michelle LeRoux Williams, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Michelle LeRoux Williams, Chief Scientific Officer of Elutia Inc. (ELUT), reported transactions on September 10, 2025.
• 12,500 restricted stock units (RSUs) vested, converting into Class A Common Stock.
• Following the vesting, 3,950 shares of Class A Common Stock were disposed of at a price of $1.36 per share to satisfy tax withholding requirements.
• After these transactions, Williams directly owns 93,385 shares of Class A Common Stock.
• She also beneficially owns 62,500 derivative securities, representing remaining unvested restricted stock units.
• The original grant of 150,000 restricted stock units occurred on January 31, 2024, with a vesting schedule extending through December 10, 2026.

Sentiment

Score: 5

Explanation: The filing details a routine insider transaction involving the vesting of restricted stock units and a tax-related sale of shares. This is a neutral event that does not inherently signal positive or negative changes in the company's fundamental outlook or operations.

Positives

• The vesting of restricted stock units indicates continued equity participation and alignment of executive interests with shareholder value.
• The transaction is a routine part of executive compensation, reflecting the fulfillment of previously established equity awards.

Negatives

• A portion of the vested shares (3,950 shares) was sold to cover tax withholding requirements, resulting in a reduction of direct share ownership.

Risks

• No new specific risks are identified in this routine insider transaction filing beyond the general market risks associated with holding company stock.

Future Outlook

The future outlook includes the continued vesting of the remaining 62,500 restricted stock units according to the established quarterly schedule, with the final vesting occurring on December 10, 2026.

Industry Context

This filing represents a routine insider transaction, common across all industries for executives who receive equity compensation. It reflects the standard process of restricted stock unit vesting and subsequent share disposition to cover tax obligations, rather than a discretionary sale based on market sentiment.

Comparison to Industry Standards

• The structure of equity compensation through restricted stock units with a multi-year vesting schedule is a common practice for executive retention and incentive across various industries, including biotechnology and medical devices, where Elutia operates.
• The sale of shares to cover tax liabilities upon vesting is a standard and expected event, aligning with typical tax treatment of equity awards for executives in publicly traded companies.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a change in company strategy or performance. The reduction in direct ownership due to tax withholding is minor in the context of total outstanding shares.
• Employees: No direct impact on general employees is indicated by this executive compensation event.

Next Steps

• Continued quarterly vesting of the remaining 62,500 restricted stock units as per the schedule outlined in the original grant, with the next vesting event expected on December 10, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives receiving equity compensation and typically do not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. The transaction is neutral in its impact on the company's valuation or strategic direction, thus a 'hold' recommendation is appropriate.

Keywords

Elutia, ELUT, Michelle LeRoux Williams, Chief Scientific Officer, CSO, Form 4, insider transaction, stock vesting, restricted stock units, RSU, equity compensation, tax withholding